Akoya Biosciences, Inc. Company profile
About Akoya Biosciences Inc
Akoya Biosciences, Inc. is a life sciences technology company. The Company deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. It provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. It offers contract research services laboratory, which is called as advanced biopharma solutions.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Akoya Biosciences Inc revenues increased 29% to $54.9M. Net loss applicable to common stockholders increased from $21.8M to $44.4M. Revenues reflect Consumables segment increase of 68% to $14.3M, Instruments segment increase of 21% to $28.7M, North America segment increase of 39% to $28M, EMEA segment increase of 21% to $14.4M. Higher net loss reflects Selling.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)